✦ LIBER ✦

EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia

✍ Scribed by Tiribelli, Mario; Bonifacio, Massimiliano; Calistri, Elisabetta; Binotto, Gianni; Maino, Elena; Marin, Luciana; Guardalben, Emanuele; Branca, Antonio; Gherlinzoni, Filippo; Semenzato, Gianpietro; Sancetta, Rosaria; Pizzolo, Giovanni; Fanin, Renato

Book ID: 122833232
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 722 KB
Volume: 37
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2013.07.037

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN73 USING SHORT-TERM RESPONSE TO PREDI

PCN73 USING SHORT-TERM RESPONSE TO PREDICT LONG-TERM OUTCOMES IN PATIENTS WITH IMATINIB-RESISTENT OR IMATINIB-INTOLERANT CHRONIC MYELOID LEUKAEMIA

✍ M Taylor; R Saxby; C Davis 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

EUTOS score predicts survival and cytoge

EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib

✍ Tao, Zhongfei; Liu, Bingcheng; Zhao, Yaozhong; Wang, Ying; Zhang, Rongli; Han, M 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 621 KB

Appearance of bone marrow lymphocytosis

Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia

✍ Mustjoki, S; Lundán, T; Knuutila, S; Porkka, K 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 225 KB

57: Outcomes for allogeneic transplantat

57: Outcomes for allogeneic transplantation in imatinib-refractory chronic myeloid leukaemia (CML) are equivalent to outcomes in imatinib-responsive/imatinib-naive CML and can be predicted by the EBMT risk score

✍ S.T. Durrant; S. Stylian; R.J. Western; J.P. Morton; J. Butler; C. Hutchins; G. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 63 KB

BCR-ABL1 transcript at 3 months predicts

BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib

✍ Kim, Dennis D.; Lee, Honggi; Kamel-Reid, Suzanne; Lipton, Jeffrey H. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 351 KB

Significance of suboptimal response to i

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

✍ Yesid Alvarado; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Gautam Borthakur 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB 👁 2 views

## Abstract ## BACKGROUND: The European LeukemiaNet recommendations for chronic myeloid leukemia (CML) defined a group of patients with suboptimal response to imatinib. The significance of this response was not well defined. ## METHODS: The significance of having had a suboptimal response during